BridGene, Takeda partner to discover drugs using chemoproteomics

By The Science Advisory Board staff writers

March 30, 2021 -- BridGene Biosciences has entered a strategic research collaboration and licensing agreement with Takeda Pharmaceutical to establish up to five drug discovery programs.

The companies will use BridGene's proprietary isobaric mass tagged affinity characterization (IMTAC) chemoproteomics platform to identify targets and small-molecule drug candidates for Takeda to pursue into clinical development. BridGene's chemoproteomics platform can identify small-molecule interactions with a wide variety of proteins in cells to discover drug candidates for hard-to-drug targets.

Under the partnership, BridGene will receive an upfront payment of an undisclosed amount for access to its IMTAC technology. For any validated targets selected by Takeda, Takeda will receive an exclusive license to research, develop, and commercialize candidates that result from the research programs. BridGene will then be eligible to receive preclinical, clinical, and commercial milestone payments that could exceed $500 million, as well as royalties from future sales of commercialized drugs.

This collaboration expands on a previous pilot program between the companies in 2020. The new partnership includes an initial research program focused on identifying targets that contribute to a disease phenotype associated with a neurodegenerative disease and is modifiable by small molecules in a phenotypic screen.

Copyright © 2021
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here